RU2007126770A - Кристаллические формы ингибитора фактора ха - Google Patents
Кристаллические формы ингибитора фактора ха Download PDFInfo
- Publication number
- RU2007126770A RU2007126770A RU2007126770/04A RU2007126770A RU2007126770A RU 2007126770 A RU2007126770 A RU 2007126770A RU 2007126770/04 A RU2007126770/04 A RU 2007126770/04A RU 2007126770 A RU2007126770 A RU 2007126770A RU 2007126770 A RU2007126770 A RU 2007126770A
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- crystalline
- powder
- ray diffractogram
- following
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000843 powder Substances 0.000 claims 10
- -1 2-oxo-2H-pyridin-1-yl Chemical group 0.000 claims 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 230000009424 thromboembolic effect Effects 0.000 claims 6
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000001757 thermogravimetry curve Methods 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 1
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010014513 Embolism arterial Diseases 0.000 claims 1
- 206010037379 Pulmonary embolism and thrombosis Diseases 0.000 claims 1
- 206010063544 Renal embolism Diseases 0.000 claims 1
- 206010042434 Sudden death Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 claims 1
- 239000003586 protic polar solvent Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002411 thermogravimetry Methods 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63638704P | 2004-12-15 | 2004-12-15 | |
| US60/636,387 | 2004-12-15 | ||
| US73798505P | 2005-11-18 | 2005-11-18 | |
| US60/737,985 | 2005-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007126770A true RU2007126770A (ru) | 2009-01-27 |
Family
ID=36384503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007126770/04A RU2007126770A (ru) | 2004-12-15 | 2005-12-14 | Кристаллические формы ингибитора фактора ха |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7371864B2 (enExample) |
| EP (1) | EP1828187A2 (enExample) |
| JP (1) | JP2008524228A (enExample) |
| KR (1) | KR20070087606A (enExample) |
| AR (1) | AR053990A1 (enExample) |
| AU (1) | AU2005317158A1 (enExample) |
| BR (1) | BRPI0519331A2 (enExample) |
| CA (1) | CA2589886A1 (enExample) |
| IL (1) | IL183825A0 (enExample) |
| MX (1) | MX2007006919A (enExample) |
| NO (1) | NO20072666L (enExample) |
| PE (1) | PE20060739A1 (enExample) |
| RU (1) | RU2007126770A (enExample) |
| TW (1) | TW200634011A (enExample) |
| WO (1) | WO2006065853A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2636757B1 (en) | 2008-05-27 | 2016-11-23 | Dako Denmark A/S | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers |
| US9303287B2 (en) | 2009-02-26 | 2016-04-05 | Dako Denmark A/S | Compositions and methods for RNA hybridization applications |
| WO2013046033A1 (en) | 2011-09-30 | 2013-04-04 | Dako Denmark A/S | Hybridization compositions and methods using formamide |
| EP3252173A1 (en) | 2011-10-21 | 2017-12-06 | Dako Denmark A/S | Hybridization compositions and methods |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI331526B (en) * | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| GEP20074098B (en) * | 2001-09-21 | 2007-05-10 | Bristol Myers Squibb Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| US20060069085A1 (en) * | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060069260A1 (en) * | 2004-09-28 | 2006-03-30 | Huiping Zhang | Preparation of N-aryl pyridones |
| US7388096B2 (en) | 2004-09-28 | 2008-06-17 | Bristol-Myers Squibb Company | Crystalline forms of a factor Xa inhibitor |
| US7304157B2 (en) * | 2004-09-28 | 2007-12-04 | Bristol-Myers Squibb Company | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
-
2005
- 2005-12-14 RU RU2007126770/04A patent/RU2007126770A/ru not_active Application Discontinuation
- 2005-12-14 WO PCT/US2005/045158 patent/WO2006065853A2/en not_active Ceased
- 2005-12-14 BR BRPI0519331-1A patent/BRPI0519331A2/pt not_active IP Right Cessation
- 2005-12-14 MX MX2007006919A patent/MX2007006919A/es active IP Right Grant
- 2005-12-14 EP EP05853961A patent/EP1828187A2/en not_active Withdrawn
- 2005-12-14 TW TW094144289A patent/TW200634011A/zh unknown
- 2005-12-14 CA CA002589886A patent/CA2589886A1/en not_active Abandoned
- 2005-12-14 JP JP2007546841A patent/JP2008524228A/ja active Pending
- 2005-12-14 US US11/302,692 patent/US7371864B2/en active Active
- 2005-12-14 KR KR1020077013364A patent/KR20070087606A/ko not_active Withdrawn
- 2005-12-14 AU AU2005317158A patent/AU2005317158A1/en not_active Abandoned
- 2005-12-14 PE PE2005001450A patent/PE20060739A1/es not_active Application Discontinuation
- 2005-12-14 AR ARP050105253A patent/AR053990A1/es unknown
-
2007
- 2007-05-25 NO NO20072666A patent/NO20072666L/no unknown
- 2007-06-10 IL IL183825A patent/IL183825A0/en unknown
-
2008
- 2008-04-09 US US12/099,906 patent/US20080188517A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0519331A2 (pt) | 2009-01-20 |
| US7371864B2 (en) | 2008-05-13 |
| JP2008524228A (ja) | 2008-07-10 |
| TW200634011A (en) | 2006-10-01 |
| US20060148846A1 (en) | 2006-07-06 |
| WO2006065853A3 (en) | 2006-08-24 |
| NO20072666L (no) | 2007-09-07 |
| KR20070087606A (ko) | 2007-08-28 |
| AR053990A1 (es) | 2007-05-30 |
| MX2007006919A (es) | 2007-06-26 |
| WO2006065853A2 (en) | 2006-06-22 |
| CA2589886A1 (en) | 2006-06-22 |
| EP1828187A2 (en) | 2007-09-05 |
| PE20060739A1 (es) | 2006-08-16 |
| AU2005317158A1 (en) | 2006-06-22 |
| US20080188517A1 (en) | 2008-08-07 |
| IL183825A0 (en) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201927T1 (hr) | PIRIMIDINONI KAO INHIBITORI FAKTORA XIa | |
| HRP20180465T1 (hr) | Kristalni oblici inhibitora faktora xia | |
| JP2014530240A5 (enExample) | ||
| JP2015533168A5 (enExample) | ||
| KR100204433B1 (ko) | 4-아미노피리미딘 유도체 | |
| JP2014532070A5 (enExample) | ||
| KR100783835B1 (ko) | 면역억제제로서 5-(벤즈-(ｚ)-일리덴-티아졸리딘-4-원유도체 | |
| JP2011520967A5 (enExample) | ||
| JP2014521701A5 (enExample) | ||
| HRP20140714T1 (hr) | Alkilamin-supstituirani dicijanopiridin i njegovi esterski amino kiselinski predlijekovi | |
| EP3360862B1 (en) | Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof | |
| JP2006528621A5 (enExample) | ||
| JP2017525744A5 (enExample) | ||
| JP2010510999A5 (enExample) | ||
| JP2007512349A5 (enExample) | ||
| JP2018515525A5 (enExample) | ||
| RU2006119776A (ru) | Производные бензо{b}{1, 4} диоксепина | |
| JP2013536864A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| WO1999005109A1 (en) | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-β INHIBITORS CONTAINING THE SAME | |
| CN110062757A (zh) | 凝血因子XIa抑制剂及其用途 | |
| RU2007126770A (ru) | Кристаллические формы ингибитора фактора ха | |
| RU2012108423A (ru) | Ацилгуанидиновые производные с азотсодержащим циклом | |
| CN1344268A (zh) | 咪唑[1,5－a]吡啶并[3,2－e]吡嗪酮作为药物的应用 | |
| RU2008119994A (ru) | Ингибиторы калиевых каналов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20090210 |